Empagliflozin Improves Cardiovascular and Renal Outcomes in Heart Failure Irrespective of Systolic Blood Pressure.

Michael Böhm,Stefan D. Anker,Javed Butler,Gerasimos Filippatos,João Pedro Ferreira,Stuart J. Pocock,Felix Mahfoud,Martina Brueckmann,Waheed Jamal,Anne Pernille Ofstad,Elke SCHüLER,Piotr Ponikowski,Christoph Wanner,Faiez Zannad,Milton Packer,EMPEROR-Reduced Trial Committees,investigators

Empagliflozin Improves Cardiovascular and Renal Outcomes in Heart Failure Irrespective of Systolic Blood Pressure.

2021

Michael Böhm
Stefan D. Anker
Javed Butler
Gerasimos Filippatos
João Pedro Ferreira
Stuart J. Pocock
Felix Mahfoud
Martina Brueckmann
Waheed Jamal
Anne Pernille Ofstad
Elke SCHüLER
Piotr Ponikowski
Christoph Wanner
Faiez Zannad
Milton Packer
EMPEROR-Reduced Trial Committees
investigators

Abstract Background Empagliflozin reduces the risk of cardiovascular death or heart failure (HF) hospitalization in patients with reduced ejection fraction. Its interplay with systolic blood pressu...

Keywords:

in patient
Blood pressure
Cardiology
cardiovascular outcomes
Ejection fraction
Empagliflozin
Heart failure
Medicine
Internal medicine
cardiovascular death

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations